Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 23, 2019

FDA approves Merck’s Pifeltro and Delstrigo for virologically suppressed HIV-1 patients

Merck has secured approval from the US Food and Drug Administration (FDA) for Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) to treat appropriate adults living with HIV-1 who are virologically suppressed.

Image: The US FDA’s Center for Drug Evaluation and Research. Photo: courtesy of The U.S. Food and Drug Administration.